EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells

Ilaria Cursaro, Luca Frattaruolo, Laura Scalvini, Chiara Contri, Alessia Bichicchi, Nicola Tardiolo, Valeria Tudino, Sara Rossi, Eugenia Nicol Manti, Martina Cappello, Chiara Papulino, Emilia Maellaro und 14 weitere

Bioorganic Chemistry · 2025-11 · 166 · 109085

DOI: 10.1016/j.bioorg.2025.109085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025-11. Verfasst von Ilaria Cursaro und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Glioblastoma, Antineoplastic Agents, Neuroblastoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agencia de Innovación y Desarrollo de Andalucía, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases 6 and 8 (HDAC6/8) have emerged as promising therapeutic targets in aggressive neural tumors such as neuroblastoma and glioblastoma. Herein, we report the design, synthesis, and comprehensive biological evaluation of a novel series of hydroxamic acid-based inhibitors (5a-p), featuring nature-inspired vanillyl CAP groups. Structure-activity relationship (SAR) analysis, supported by molecular docking, elucidated the role of CAP, connecting unit, and linker structure, alongside zinc-binding group orientation, on isoform selectivity and potency. Among the series, compound 5o emerged as a highly potent and preferential HDAC6 inhibitor (IC50 = 4.5 nM). In SH-SY5Y neuroblastoma cells, 5o induced dose-dependent α-tubulin hyperacetylation, caspase-3/7 activation that indicates apoptosis, a minor autophagy stimulation and showing negligible cytotoxicity in HEK-293 cells. Furthermore, 5o significantly reduced cell viability in multiple glioblastoma models (U87-MG, T98G, U251-MG), disrupting mitotic progression and promoting G2/M cell cycle arrest, as evidenced by decreased phosphorylation of p-cdc2 (Tyr15). These findings validate the therapeutic relevance of HDAC inhibition in neural tumors and suggest that compound 5o deserves further investigation as an epigenetic modulator in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsGlioblastomaAntineoplastic AgentsNeuroblastomaHydroxamic AcidsHumansStructure-Activity RelationshipDrug Screening Assays, AntitumorCell ProliferationMolecular StructureDose-Response Relationship, DrugHistone Deacetylase 6ApoptosisCell Line, TumorMolecular Docking SimulationHistone DeacetylasesCell Survival

Stichwörter der Autor:innen

HDAC inhibitorsapoptosiscell cycle arrestglioblastomaneuroblastoma

Substanzen

Histone Deacetylase InhibitorsAntineoplastic AgentsHistone Deacetylase 6Hydroxamic AcidsHDAC6 protein, humanHistone Deacetylases

Autor:innen und Institutionen

  • Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
  • Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Edificio Polifunzionale, 87036 Rende, (CS), Italy.
  • Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, Campus Universitario, 43124 Parma, Italy.
  • Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy.
  • Department of Life Sciences, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
  • Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via de Crecchio 7, 80138, Naples, Italy.

Förderung

  • Agencia de Innovación y Desarrollo de Andalucía
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Cursaro, I., Frattaruolo, L., Scalvini, L., Contri, C., Bichicchi, A., Tardiolo, N., Tudino, V., Rossi, S., Manti, E. N., Cappello, M., Papulino, C., Maellaro, E., Marcolongo, P., Benedetti, R., Altucci, L., Varani, K., Mor, M., Frosini, M., Vincenzi, F., …, & Campiani, G. (2025). New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells. Bioorganic Chemistry, 166, 109085. https://doi.org/10.1016/j.bioorg.2025.109085

Vancouver

Cursaro I, Frattaruolo L, Scalvini L, Contri C, Bichicchi A, Tardiolo N, et al. New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells. Bioorganic Chemistry. 2025;166:109085. doi:10.1016/j.bioorg.2025.109085

BibTeX
@article{Cursaro2025,
  author = {Cursaro, Ilaria and Frattaruolo, Luca and Scalvini, Laura and Contri, Chiara and Bichicchi, Alessia and Tardiolo, Nicola and Tudino, Valeria and Rossi, Sara and Manti, Eugenia Nicol and Cappello, Martina and Papulino, Chiara and Maellaro, Emilia and Marcolongo, Paola and Benedetti, Rosaria and Altucci, Lucia and Varani, Katia and Mor, Marco and Frosini, Maria and Vincenzi, Fabrizio and Cappello, Anna Rita and Lodola, Alessio and Saponara, Simona and Butini, Stefania and Carullo, Gabriele and Gemma, Sandra and Campiani, Giuseppe},
  title = {New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells},
  journal = {Bioorganic Chemistry},
  year = {2025},
  volume = {166},
  pages = {109085},
  doi = {10.1016/j.bioorg.2025.109085}
}
Kostenlos starten →